CHD1 is a synthetic lethal vulnerability in MYC-driven breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Chromatin Biology

Background:

• The MYC transcription factor is crucial for cell growth but drives cancer when dysregulated.
• Directly targeting MYC has proven challenging, necessitating alternative therapeutic strategies.
• Understanding MYC's oncogenic mechanisms is key to developing new cancer treatments.

Purpose of the Study:

• To identify novel therapeutic targets in MYC-driven breast cancer.
• To investigate the role of chromatin remodeling in MYC-driven cancers.
• To explore synthetic lethal interactions involving MYC.

Main Methods:

• Genome-wide screens to identify potential synthetic lethal targets.
• In vitro cell culture models to assess proliferation and cell death.
• In vivo xenograft models to evaluate tumor growth suppression.
• Mechanistic studies on chromatin landscape and transcriptional programs.

Main Results:

• Loss of Chromodomain-Helicase DNA-binding 1 (CHD1) was identified as a synthetic lethal target in MYC-driven breast cancer.
• Knockdown of CHD1 suppressed tumor growth in vivo and reduced cell proliferation/induced cell death in vitro, particularly when MYC was overexpressed.
• CHD1 maintains an open chromatin state and a pro-cancer transcriptional program in MYC-overexpressing cells.
• Synthetic lethality appears to result from nucleolar stress and p53 activation.

Conclusions:

• CHD1 is essential for maintaining the malignant phenotype in MYC-driven breast cancer.
• CHD1 represents a novel synthetic vulnerability and potential therapeutic target for MYC-driven breast cancers.
• These findings offer new insights into chromatin regulation in MYC-driven oncogenesis.